Parkinsonism-Hyperpyrexia syndrome in Parkinson's disease

Movement Disorder Emergencies: Diagnosis and Treatment: Second Edition

Volumn , Issue , 2013, Pages 29-41

  Huddleston, Daniel E ^a   Factor, Stewart A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84921646953     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60761-835-5_3     Document Type: Chapter

References (47)

1. Factor SA. Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation. Mov Disord. 2007;22:148-9.
2. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris). 1960;118:145-52.
3. Delay J, Denicker P. Drug induced extrapyramidal syndromes. In: Vinken P, Bruyun G, editors. Handbook of clinical neurology. Amsterdam: North Holland; 1968. p. 258-9.
4. Factor S. Neuroleptic malignant syndrome. In: Factor S, Lang A, Weiner W, editors. Drug induced movement disorders. 2nd ed. Mount Kisco, NY: Blackwell Publishing; 2005. p. 174-212.
5. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79-83.
6. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986;73:337-47.
7. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146:717-25.
8. Kurlan R, Hamill R, Shoulson I. Neuroleptic malignant syndrome. Clin Neuropharmacol. 1984;7:109-20.
9. Mueller P. Diagnosis and treatment of neuroleptic malignant syndrome: a review. Neuroview. 1987;3:1-5.
10. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology. 1981;31:1022-5.
11. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-13.
12. Kosten TR, Kleber HD. Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse. 1988;14:335-46.
13. Toro M, Matsuda O, Mikizuich K, Sugano K. Neuroleptic malignant syndrome-like state following withdrawal of antiparkinsonian drugs. J Nerv Ment Dis. 1981;169:324-7.
14. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant like syndrome due to levodopa therapy withdrawal. JAMA. 1985;254:2792-5.
15. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord. 2001;16:960-2.
16. Pfeiffer RF, Sucha EL. "On-off"-induced lethal hyperthermia. Mov Disord. 1989;4:338-41.
17. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or-dopaminergic malignant syndrome- due to levodopa therapy withdrawal; clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9:175-8.
18. Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med. 1991;151:794-6.
19. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10:136-40.
20. Onofrj M, Bonanni L, Cossu G, Manca D, Stocchi F, Thomas A. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Relat Disord. 2009;15 Suppl 3:S233-6.
21. Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord. 2005;20:322-34.
22. Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies part 1: hypokinetic disorders. Arch Neurol. 2011;68:567-72.
23. Sechi GP, Tanda F, Mutani R. Fatal hyperpyrexia after withdrawal of levodopa. Neurology. 1984;34:249-51.
24. Figa-Talamanca L, Gualandi C, Di Meo L, Di Battista G, Neri G, Lo Russo F. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology. 1985;35:258-61.
25. Hirschorn KA, Greenberg HS. Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome; a case report. Clin Neuropharmacol. 1988;11:278-81.
26. Mayeux R, Stern Y, Mulvey K, Cote L. Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease. N Engl J Med. 1985;313:724-8.
27. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115-38.
28. Iwuagwu CU, Riley D, Bonoma RA. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor. Am J Med. 2000;108:517-8.
29. Cunningham MA, Darby DG, Donnan GA. Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction. Neurology. 1991;41:942-3.
30. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. 1981;31:132-7.
31. Mizuta E, Yamasaki S, Nakatake M, Kuno S. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology. 1993;43:1048-9.
32. Cao L, Katz RH. Acute hypernatremia and neuroleptic malignant syndrome in Parkinson disease. Am J Med Sci. 1999;318:67-8.
33. Bonnici A, Ruiner CE, St-Laurent L, Hornstein D. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay. Ann Pharmacother. 2010;44:1504-7.
34. The Deep Brain Stimulation For Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345:956-63.
35. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology. 2002;58:396-401.
36. Kleiner-Fisman G, Saint-Cyr JA, Miyasaki J, Lozano A, Lang AE. Subthalamic DBS replaces levodopa in Parkinson's disease. Neurology. 2002;59:1293-4.
37. Kadowaki T, Hashimoto K, Suzuki K, Watanabe Y, Hirata K. Case report: recurrent parkinsonism- hyperpyrexia syndrome following discontinuation of subthalamic deep brain stimulation. Mov Disord. 2011;26(8):1561-2. 10.1002/mds.23596.
38. Kim JH, Kwon TH, Koh SB, Park JY. Parkinsonism-hyperpyrexia syndrome after deep brain stimulation surgery: case report. Neurosurgery. 2010;66:E1029.
39. Sato Y, Asoh T, Metoki N, Satoh K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74:574-6.
40. Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology. 1999;52:777-81.
41. Ueda M, Hamamoto M, Nagayama H, Okubo S, Amemiya S, Katayama Y. Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry. 2001;71:111-3.
42. Kuno S, Komure O, Mizuta E, Yamasaki S, Nishitani H. Neuroleptic malignant syndrome associated with withdrawal of antiparkinsonian drugs. In: Nagatsu T, Fisher A, Yoshida M, editors. Basic clinical and therapeutic aspects of Alzheimer's and Parkinson's disease. New York: Plenum Press; 1990. p. 245-8.
43. Yamawaki Y, Ogawa N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. Intern Med. 1992;31:1298-302.
44. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Eng J Med. 2004;351:2498-508.
45. Genis D. Neuroleptic malignant syndrome: impaired dopaminergic systems? Neurology. 1985;35:1806.
46. Konagaya M, Goto Y, Matsuoka Y, Konishi T, Konagaya Y. Neuroleptic malignant syndromelike condition in multiple system atrophy. J Neurol Neurosurg Psychiatry. 1997;63:120-1.
47. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000;15:201-11.